Q-linea Ab · OMXSTO:QLINEA
Q-linea Ab — Q3 2026 Earnings Presentation
14 slides from Q-linea Ab's earnings presentation, Oct 30, 2026
Slide 1: 2026 Q3 Report
2026 Q3 Report October 30th, 2026
Slide 2: Disclaimer
Disclaimer THIS PERESNTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL. T
Slide 3: Topics for today
❖ Commercial update Topics for ❖ Outlook and priorities today ❖ Financial update ❖ Respond to your questions
Slide 4: Key messages for today
Key messages for today Six ASTar instruments contracted since previous report (+25%) incl. 1 two in U.S., three in Europe and one in Asia Framework Agreement with Premier1 signed which makes ASTar 2 available for thousands of member hospitals in the U.S. Isolate RUO Kit launched expanding value of A
Slide 5: Q-linea revolutionising AST | Flagship ASTar platform designed to save lives
Q-linea revolutionising AST | Flagship ASTar platform designed to save lives Fully-automated, random 1st access platform Minutes hands-on time ~2 simple interface, load-and-go system ➢ Comprehensive menu ➢ High reproducibility ➢ High throughput with 12 Hours turn-around time samples in parallel ~6 s
Slide 6: A new standard of care | Critical patient testing moving to rapid AST
A new standard of care | Critical patient testing moving to rapid AST Current standard of care Emerging new standard of care Clinical value (~$1.5 billion global market1) ($600 – 900 million global opportunity1) of information Colony-based AST Positive Blood Culture AST Whole Blood AST ❖ 5 – 7m bloo
Slide 7: Commercial development | Six new placements contracted
Commercial development | Six new placements contracted Evaluation and/or Contracted ASTar ASTar instruments in ASTar patient tests Contracting processes 1 placements Clinical Use (MSEK) 5.6 Evaluation 22 5.4 99 30 2 21 Contracting 96 4.6 89 83 24 4.1 16 21 19 14 17 12 3.0 56 12 38 1.8 31 7 5 1.3 4 D
Slide 8: Isolate launch | Dedicated Isolate kit for Research Use Only
Isolate launch | Dedicated Isolate kit for Research Use Only ASTar Isolate G- RUO Kit | Dots indicate where MIC results available ❖ Enables testing of Gram-negative isolates on ASTar ❖ Combines dedicated isolate consumable with the established ASTar workflow and broad antimicrobial panel ❖ Designed
Slide 9: Global expansion | First commercial results from international campaign
Global expansion | First commercial results from international campaign ❖ First clinical deployment of ASTar in Asia with shipment in Q3 for installation in Q4 2026 ❖ Expected decision for national tender in Saudi Arabia during Q4 2026 ❖ ASTar launched in India: conferences in Q3 and Q4 to showcase
Slide 10: Short-term priorities | Push for strong close of 2026
Short-term priorities | Push for strong close of 2026 Commercial ❖ Conversion drive for Q4 to close year strong, incl. ongoing U.S. “Verify & Adopt” program priorities ❖ Reduce cycle times: validations vs. evaluations, GPO contracting, LIS preparation, stewardship ❖ Clinician engagement to anchor ra
Slide 11: Financial highlights | Q3 2026
Financial highlights | Q3 2026 ❖ Instruments contracted: 3 (5); total contracted base: 27 (17) ❖ Three additional systems contracted after the period (total contracted base now 30) ❖ Instruments installed: 1 (7); total installed base: 22 (12) ❖ Net sales: 4.8 MSEK (3.5) ❖ Consumables: 1.9 MSEK (1.6)
Slide 12: OPEX development | Run rate cost level below 10.5 MSEK per month
OPEX development | Run rate cost level below 10.5 MSEK per month ❖ In Q3 average operating expenses per month was 9 MSEK (12) ❖ OPEX outlook for Q4 is below 10.5 MSEK ❖ Further operating efficiencies will offset planned investments into commercial team and activities going into 2027 ❖ No. of employe
Slide 13: Key topics for Q-linea going forward financially
Key topics for Q-linea going forward financially Cost discipline ❖ Keeping monthly operating expenses stable while still funding commercial growth. Strong capital recovery ❖ A better return per placed instrument, faster payback, higher test volumes, more US contracts and more capital- purchase place
Slide 14: Thank you!
Thank Questions? you!